Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44‐ALK Fusion: A Case Report and Literature Review
ABSTRACT Neuroendocrine tumor (NET) is a deadly malignancy disease that can be found anywhere in the body. The lack of tumor‐specific treatment led to the worse prognosis of NET. Anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs), such as alectinib and crizotinib, have been used in the...
Saved in:
| Main Authors: | Haiyang Chen, Yingxi Wu, Xuan Wu, Kai Wang, Qingxin Xia, Qiming Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.70040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01) -
Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01) -
A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
by: Zhongzhao Wang, et al.
Published: (2024-11-01) -
RL4CEP: reinforcement learning for updating CEP rules
by: Afef Mdhaffar, et al.
Published: (2025-01-01) -
MBNL2-ALK: A novel ALK fusion transcript in a sinonasal melanoma
by: Elena Bolzacchini, et al.
Published: (2024-12-01)